MedTrace Logo

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

NCT00285402 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2008-02-08

No results posted yet for this study

Summary

The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a reduction in the number of migraine days.

Conditions

  • Migraine
  • Migraine Headache
  • Migraine Disorders
  • Migraine With Aura
  • Migraine Without Aura

Interventions

DRUG

AST-726 Low dose

DRUG

AST-726 High dose

DRUG

AST-726 Placebo

Sponsors & Collaborators

  • Ariston Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • W. M. Mulleners · Canisius-Wilhelmina Zeikenhuis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Finland
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285402 on ClinicalTrials.gov